Crossmark

Fingolimod as an effective therapeutic strategy for pediatric relapsing-remitting multiple sclerosis: two case reports

Published Online: 2021-04-27

Published Print: 2021-05

Authors

Zanetta, Chiara

Filippi, Massimo https://orcid.org/0000-0002-5485-0479
Moiola, Lucia
License Information

Text and Data Mining valid from 2021-04-27

Version of Record valid from 2021-04-27
More Information

Article History

Received: 11 November 2020

Accepted: 16 April 2021

First Online: 27 April 2021

Declarations

:

: Dr. Zanetta has nothing to disclose.Dr. Moiola received compensation for speaking activities, and/or consulting services from Merck, Biogen, Novartis, Roche, Sanofi, and TEVAProf. Filippi is the Editor-in-Chief of the Journal of Neurology and Associate Editor of Human Brain Mapping; received compensation for consulting services and/or speaking activities from Almiral, Alexion, Bayer, Biogen, Celgene, Eli Lilly, Genzyme, Merck-Serono, Novartis, Roche, Sanofi, Takeda, and Teva Pharmaceutical Industries; and receives research support from Biogen Idec, Merck-Serono, Novartis, Roche, Teva Pharmaceutical Industries, Italian Ministry of Health, Fondazione Italiana Sclerosi Multipla, and ARiSLA (Fondazione Italiana di Ricerca per la SLA).

: Ethical approval was obtained from the ethics committee of the IRCCS Ospedale San Raffaele.

: Informed consent to participate was obtained from legal guardians.

: Informed consent to publish was obtained from legal guardians.

Document is current